Cryoport (CYRX) Set to Report Q4 FY2025 Earnings After the Bell — Here’s What to Expect

https://misryoum.com/us/markets/cryoport-cyrx-set-to-report-q4-fy2025-earnings/

Consensus Estimates Metric Q4 FY2025 Estimate Q4 FY2024 Actual YoY Change Revenue ~$40–50M ~$59.5M ~-24% EPS (Non-GAAP) — — Watching for cash burn Active Clinical Programs Supported Watching for stabilization — Key leading indicator Analyst consensus: Strong Buy (9...

#Cryoport #CYRX #Set #Report #FY2025 #Earnings #After #the #Bell #Heres #What #Expect #US_News_Hub #misryoum_com

UBS upgrades Cryoport to 'buy' from 'neutral', setting $10 target price amid positive outlook for cell and gene therapy services expansion and expected free cash flow growth
#YonhapInfomax #UBS #Cryoport #InvestmentUpgrade #BiotechStocks #GeneTherapy #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=55505
UBS Upgrades Cryoport from Neutral to Buy

UBS upgrades Cryoport to 'buy' from 'neutral', setting $10 target price amid positive outlook for cell and gene therapy services expansion and expected free cash flow growth

Yonhap Infomax